In a press release issued on September 2, 2008, InterMune, Inc. (the "Company") announced that it has earned a $15 million development milestone under its development collaboration with Hoffmann-La Roche Inc. and F.Hoffman-La Roche Ltd. (collectively, "Roche") for the hepatitis C virus (HCV) NS3 protease inhibitor compound ITMN-191 (referred to as R7227 at Roche). Under the terms of their 2006 collaboration agreement, the Company and Roche are collaborating to develop and commercialize products from the Company's HCV protease inhibitor program and the clinical program for ITMN-191 is now being transitioned from the Company to Roche which, starting in Phase 2, will have primary responsibility for completing the global development and registration program.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.

   (d) Exhibits.

 Exhibit No.        Description

       99.1         Press release dated September 2, 2008 announcing a $15 million
                    development milestone payment by Roche to the Company and that Roche
                    will lead the ITMN-191 program starting in Phase 2.